ZNTL – zentalis pharmaceuticals, inc. - common stock (US:NASDAQ)

News

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit [Yahoo! Finance]
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at HC Wainwright from $46.00 to $40.00. They now have a "buy" rating on the stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Stifel Nicolaus from $36.00 to $32.00. They now have a "buy" rating on the stock.
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com